The Pennant Group (PNTG) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for May 16, 2025, with voting on five key proposals, including director elections, amendments to the certificate of incorporation, incentive plan updates, auditor ratification, and executive compensation approval.
Only shareholders of record as of March 18, 2025, are eligible to vote, with 34,722,287 shares outstanding.
Proxy materials and the 2024 Annual Report are available online, and multiple voting methods are provided.
Voting matters and shareholder proposals
Election of two Class III directors: Stephen M.R. Covey (incumbent) and Suzanne D. Snapper (new nominee), both deemed independent.
Amendment to certificate of incorporation to allow officer exculpation under Delaware law, aligning officer protections with those of directors.
Approval of the Amended and Restated 2019 Omnibus Incentive Plan, adding 3,275,000 shares and updating plan provisions.
Ratification of Deloitte & Touche LLP as independent auditor for 2025.
Advisory vote on executive compensation (Say-on-Pay).
Board of directors and corporate governance
Board is classified into three staggered classes, with annual elections for one class.
Majority of directors are independent per Nasdaq rules; independent directors meet in executive session annually.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Quality Assurance and Compliance.
Board leadership structure currently combines CEO and Chairman roles, with a lead independent director.
Director compensation includes cash retainers and restricted stock grants, benchmarked to peer companies.
Latest events from The Pennant Group
- Major acquisitions fuel growth, with integration and margin expansion as top priorities.PNTG
Oppenheimer 36th Annual Healthcare MedTech & Services Conference18 Mar 2026 - Record 2025 growth and acquisitions set the stage for further expansion in 2026.PNTG
Q4 202526 Feb 2026 - Expanding in the Southeast, leveraging local leadership, and preparing for regulatory changes.PNTG
Jefferies 2025 Healthcare Services Conference3 Feb 2026 - Q2 revenue up 27.6%, net income doubled, and guidance raised on strong segment growth.PNTG
Q2 20242 Feb 2026 - Q3 revenue up 28.9% to $180.7M, adjusted EPS $0.26, and guidance raised for 2024.PNTG
Q3 202415 Jan 2026 - Leadership-driven growth, payer diversity, and M&A fuel recovery and expansion amid regulatory shifts.PNTG
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026 - Disciplined growth, leadership investment, and tech adoption drive strong outlook for 2025.PNTG
Oppenheimer 35th Annual Health Care MedTech and Services Conference26 Dec 2025 - Record 2024 revenue and net income growth, with double-digit gains expected in 2025.PNTG
Q4 20242 Dec 2025 - Proxy covers director elections, incentive plan expansion, and key governance and compensation votes.PNTG
Proxy Filing2 Dec 2025